Jump to content

AMNOG

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Buidhe (talk | contribs) at 01:55, 9 December 2023 (Moving from Category:Pharmaceutical industry to Category:Drug development using Cat-a-lot). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

The Arzneimittelmarkt-Neuordnungsgesetz (AMNOG, English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of pharmaceutical products in Germany. It requires drug manufacturers to submit evidence to the Federal Joint Committee (Germany) that shows whether their new products have an added benefit compared to previous products.[1] It is credited with reducing the cost of healthcare in Germany.[2]

References

[edit]
  1. ^ "AMNOG - evaluation of new pharmaceutical". GKV-Spitzenverband. 2014. Archived from the original on 2014-05-27. Retrieved 27 May 2014.
  2. ^ Olga Khazan (22 May 2014). "Why Medicine Is Cheaper in Germany". The Atlantic.

See also

[edit]
Flag of GermanyJustice icon

This article about German law is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=AMNOG&oldid=1189003881"